Cary J. Claiborne
2023 - ADIAL PHARMACEUTICALS
In 2023, Cary J. Claiborne earned a total compensation of $801.6K as Chief Executive Officer and Member of the Board of Directors at ADIAL PHARMACEUTICALS, a 21% decrease compared to previous year.
Compensation breakdown
Bonus | $190,000 |
---|---|
Option Awards | $73,314 |
Salary | $465,625 |
Other | $72,682 |
Total | $801,621 |
Claiborne received $465.6K in salary, accounting for 58% of the total pay in 2023.
Claiborne also received $190K in bonus, $73.3K in option awards and $72.7K in other compensation.
Rankings
In 2023, Cary J. Claiborne's compensation ranked 1,464th out of 3,006 executives tracked by ExecPay. In other words, Claiborne earned more than 51.3% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 1,464 out of 3,006 | 51st |
Division Manufacturing | 867 out of 1,650 | 48th |
Major group Chemicals And Allied Products | 565 out of 918 | 39th |
Industry group Drugs | 549 out of 881 | 38th |
Industry Pharmaceutical Preparations | 386 out of 637 | 39th |
Source: SEC filing on September 27, 2024.
Claiborne's colleagues
We found two more compensation records of executives who worked with Cary J. Claiborne at ADIAL PHARMACEUTICALS in 2023.